Skip to main content
SpringerLink
Log in

Telbivudine

A Review of its Use in Compensated Chronic Hepatitis B

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Telbivudine (Sebivo®; Tyzeka®) is a synthetic nucleoside analogue that inhibits replication of hepatitis B virus (HBV). It is used in the treatment of adults with chronic hepatitis B (CHB) with evidence of viral replication and persistently elevated serum ALT and/or AST levels, and/or histological evidence of active disease.

Telbivudine is a potent antiviral that provides effective and sustained viral suppression in patients with compensated CHB. In clinical trials, treatment outcomes were improved significantly more with telbivudine 600 mg once daily than with lamivudine 100 mg or adefovir 10 mg once daily, and telbivudine-treated patients had significantly less viral resistance than lamivudine-treated patients. Increasing rates of hepatitis B e antigen (HBeAg) seroconversion were achieved in HBeAg-positive patients during periods of up to 4 years continuous telbivudine treatment, and seroconversion was durable in most patients throughout a 2-year, off-treatment follow-up, indicating the potential for a finite treatment period in this group of patients. Telbivudine is associated with a medium genetic barrier to resistance and, as patients with undetectable HBV DNA levels have significantly improved outcomes, it is recommended that HBV DNA levels are monitored at week 24 (and 6 monthly thereafter), with the addition of a nucleoside/nucleotide analogue without cross resistance (such as adefovir dipivoxil) if viraemia is present to reduce the risk of resistance (Roadmap concept). Telbivudine was generally well tolerated in clinical trials for periods of up to 4 years, and has a similar tolerability profile to that of lamivudine. A minority of telbivudine-treated patients experience creatinine kinase elevation, usually transient, and myopathy occurs rarely. In modelled cost effectiveness studies in several Asian countries, treatment with telbivudine Roadmap was cost effective in HBeAg-positive patients. Thus, telbivudine provides a valuable treatment option in CHB, particularly when administered using the Roadmap concept in HbeAg-positive patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV
Table V
Table VI
Table VII
Fig. 2

Similar content being viewed by others

References

  1. World Health Organization. Hepatitis B: fact sheet [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs204/en/index.html [Accessed 2010 Mar 3]

  2. Cooke GS, Main J, Thursz MR. Treatment for hepatitis B. BMJ 2010; 340: 87–91

    Article  Google Scholar 

  3. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15: 1356–61

    Article  PubMed  CAS  Google Scholar 

  4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227–42

    Article  Google Scholar 

  5. Berg T, Benhamou Y, Calleja JL, et al. A survey of chronic hepatitis B patient management practices in the European Union. J Viral Hepat 2010; 17(9): 624–30

    PubMed  CAS  Google Scholar 

  6. Akuta N, Kumada H. Influence of hepatitis B virus genotypes on the response to antiviral therapies. J Antimicrob Chemother 2005; 55: 139–42

    Article  PubMed  CAS  Google Scholar 

  7. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009 Sep; 50(3): 661–2

    Article  PubMed  Google Scholar 

  8. Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006; 11(6): 669–79

    PubMed  CAS  Google Scholar 

  9. Liaw Y-F. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009; 3: 425–33

    Article  PubMed  Google Scholar 

  10. Liaw YF, Lau GK, Kao JH, et al. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. Epub 2010 Mar 18

  11. Liaw Y-F, Leung N, Kao J-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263–83

    Article  PubMed  Google Scholar 

  12. Keam SJ. Telbivudine. Drugs 2007; 67(13): 1917–29

    Article  PubMed  CAS  Google Scholar 

  13. European Medicines Agency. Sebivo® 600mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/docs//en_GB/document_library/EPAR_-_Product_Information/human/000713/WC5000049337.pdf [Accessed 2010 May 21]

  14. Novartis Pharmaceuticals Corporation. Tyzeka® (telbivudine) tablets and oral solution. US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/tyzeka.pdf [Accessed 2010 May 12]

  15. Jarvis B, Faulds D. Lamivudine: a review of its therapeutic potential in chronic hepatitis B [published erratum appears in Drugs 1999; 58: 587]. Drugs 1999 Jul; 58(1): 101–41

    Article  PubMed  CAS  Google Scholar 

  16. Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003; 63(20): 2215–34

    Article  PubMed  CAS  Google Scholar 

  17. Perry C, Simpson D. Tenofovir disoproxil fumarate: in chronic hepatitis B. Drugs 2009; 69(16): 2245–56

    Article  PubMed  CAS  Google Scholar 

  18. Scott LJ, Keating GM. Entecavir: a review of its use in chronic hepatitis B. Drugs 2009; 69(8): 1003–33

    Article  PubMed  CAS  Google Scholar 

  19. Avila C, Karwowska S, Lai C-H. Telbivudine shows no activity against 8 different clinical HIV isolates and 2 multi-drug resisatnt HIV isolates [abstract no. 551]. J Hepatol 2009; 50 Suppl.1: S 204. Plus poster presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL); 2009 Apr 22–26; Copenhagen

    Google Scholar 

  20. Lin K, Karwowska S, Lam E, et al. Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. Antimicrob Agents Chemother 2010; 54(6): 2670–3

    Article  PubMed  CAS  Google Scholar 

  21. Delaney WEIV, Yang H, Miller MD, et al. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004 Oct; 48(10): 3702–10

    Article  PubMed  CAS  Google Scholar 

  22. Zhu Y, Curtis M, Qi X, et al. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/ nucleotide analogues. Antivir Chem Chemother 2009; 19(4): 165–76

    PubMed  Google Scholar 

  23. Patty A, Li B, Serra I, et al. In vitro anti-HBV activity of telbivudine/tenofovir and telbivudine/entecavir combinations [abstract no. 958]. Hepatology 2007 Oct; 46 (4 Suppl. 1): 663

    Google Scholar 

  24. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005 Aug; 129(2): 528–36

    PubMed  CAS  Google Scholar 

  25. Lai CL, Leung NW, Teo EK, et al. Phase IIb extendedtreatment trial of telbivudine vs lamivudine vs combination treatment in hepatitis B patients: two-year results [abstract no. 320]. Gastroenterology 2005 Apr; 128 (4 Suppl. 2): 692

    Article  Google Scholar 

  26. Suh DJ, Um SH, Herrmann E, et al. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study in patients with HBeAg-positive chronic hepatitis B. Antimicrob Agents Chemother 2010 Mar; 54(3): 1242–7

    Article  PubMed  CAS  Google Scholar 

  27. Seifer M, Patty A, Serra I, et al. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res 2009 Feb; 81(2): 147–55

    Article  PubMed  CAS  Google Scholar 

  28. Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10(5): 625–33

    PubMed  CAS  Google Scholar 

  29. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009 Feb; 136(2): 486–95

    Article  PubMed  CAS  Google Scholar 

  30. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007 Dec 20; 357(25): 2576–88

    Article  PubMed  CAS  Google Scholar 

  31. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008 Feb; 47(2): 447–54

    Article  PubMed  CAS  Google Scholar 

  32. Safadi R, Xie Q, Chen Y, et al. The efficacy of switching to telbivudine (LTD) in chronic hepatitis B (CHB) patients previously treated with lamivudine (LAM) [abstract no. PE158 plus poster]. 19th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2009 Feb 13–16; Hong Kong

  33. Hsu CW, Chen YC, Liaw YF, et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from GLOBE and 015 studies in chronic hepatitis B patients [abstract plus poster no. 911]. 44th Annual Meeting of the European Association for the Study of the Liver (EASL); 2009 Apr 22–26; Copenhagen

  34. Jia J-D, Gane E, Wang Y, et al. Prolonged efficacy and safety of 4 years continuous telbivudine treatment in chronic hepatitis B (CHB) patients from GLOBE and 015 studies [abstract plus poster]. 20th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2010 Mar 25–28; Beijing

  35. Wu ZG, Yan WM, Guo W, et al. Telbivudine preserves T-helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis. J Viral Hepat 2010; 17 Suppl. 1: 24–33

    Article  Google Scholar 

  36. Evans A, Riva A, Cooksley H, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008; 48: 759–69

    Article  PubMed  Google Scholar 

  37. Zhang L, Chen M, Zhang DZ, et al. The dynamic change of Th1/Th2 type cytokines in peripheral blood and its clinical significance in the hepatitis B e antigen positive patients treated with telbivudine [abstract no. PE200]. Hepatol Int 2009; 3: 136

    CAS  Google Scholar 

  38. Fisicaro P, Valdatta C, Massari M, et al. Anti-viral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010 Feb; 138(2): 682–93

    Article  PubMed  CAS  Google Scholar 

  39. Peng G, Li S, Wu W, et al. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008 Feb; 45(4): 963–70

    Article  PubMed  CAS  Google Scholar 

  40. Xie Z, Chen Y, Zhao S, et al. Intrahepatic PD-1/PD-L1 upregulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest 2009; 38(7): 624–38

    Article  PubMed  CAS  Google Scholar 

  41. Zhou XJ, Lloyd DM, Chao GC, et al. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol 2006 Mar; 46(3): 275–81

    Article  PubMed  CAS  Google Scholar 

  42. Dong M, Persohn E, Grenet O, et al. Absence of mitochondrial toxicity of telbivudine in skeletal muscle cells, hepatocytes, and neuronal cells from rat or human [abstract plus poster]. 48th Annual Meeting of the Society of Toxicology; 2009 Mar 15–19; Baltimore (MD)

  43. Bridges EG, Selden JR, Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. Antimicrob Agents Chemother 2008 Jul; 52(7): 2521–8

    Article  PubMed  CAS  Google Scholar 

  44. Poordad F, Zeldin G, Harris SI, et al. Absence of effect of telbivudine on cardiac repolarization: results of a thorough QT/QTc study in healthy participants. J Clin Pharmacol 2009 Dec; 49(12): 1436–46

    Article  PubMed  CAS  Google Scholar 

  45. International Conference on Harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs [online]. Available from URL:http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf [Accessed 2010 Jun 3]

  46. Hu P, Jiang J, Wang H, et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J Clin Pharmacol 2006 Sep; 46(9): 999–1007

    Article  PubMed  CAS  Google Scholar 

  47. Zhou XJ, Fielman BA, Lloyd DM, et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother 2006; 50(7): 2309–15

    Article  PubMed  CAS  Google Scholar 

  48. Lai CL, Lim SG, Brown NA, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004 Sep; 40(3): 719–26

    Article  PubMed  CAS  Google Scholar 

  49. Zhou XJ, Lim SG, Lloyd DM, et al. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother 2006 Mar; 50(3): 874–9

    Article  PubMed  CAS  Google Scholar 

  50. Zhou XJ, Marbury TC, Alcorn HW, et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob Agents Chemother 2006 May; 50(5): 1721–6

    Article  PubMed  CAS  Google Scholar 

  51. Zhou XJ, Swan S, Smith WB, et al. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 2007 Dec; 51(12): 4231–5

    Article  PubMed  CAS  Google Scholar 

  52. Zhou XJ, Ke J, Sallas WM, et al. Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment. J Clin Pharmacol 2009 Jun; 49(6): 725–34

    Article  PubMed  CAS  Google Scholar 

  53. Wang Y, Jia J, Hou J, et al. A phase III comparative trial of telbivudine vs lamivudine in Chinese patients with chronic hepatitis B: two-year results [abstract no. S1768]. Digestive Disease Week; 2007 May 19–24; Washington, DC

  54. Chen YC, Hsu CW, Liaw YF, et al. Efficacy of 3 years of telbivudine treatment for patients with genotype B/C chronic hepatitis B [abstract no. 349 plus poster]. 44th Annual Meeting of the European Association for the Study of the Liver (EASL); 2009 Apr 22–26; Copenhagen

  55. Jia J-D, Hou J-L, Yin Y-K, et al. Prolonged efficacy and safety of 3 years’ continuous telbivudine treatment in Chinese chronic hepatitis B patients [abstract plus poster]. 19th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2009 Feb 13–16; Hong Kong

  56. Ren H, Wang Y, Thongsawat S, et al. Telbivudine-induced HBeAg seroconversion in chronic hepatitis B (CHB) patients is durable during 2 years off-treatment follow-up [poster no. 190]. 20th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2010 Mar 25–28; Beijing

  57. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009 Jul; 51(1): 11–20

    Article  PubMed  CAS  Google Scholar 

  58. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007 Dec 4; 147(11): 745–54

    PubMed  Google Scholar 

  59. Zheng M-H, Shi K-Q, Dai Z-J, et al. A 24-week, parallell-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of HBeAg-positive chronic hepatitis B [abstract]. 45th Annual Meeting of the European Association for the Study of the Liver (EASL); 2010 Apr 14–18; Vienna

  60. Liang J, Han T, Xiao SX. Telbivudine treatment on cirrhosis resulting from chronic hepatitis B [in Chinese]. Chin J Hepatol 2009 Jan; 17(1): 24–7

    Article  CAS  Google Scholar 

  61. Moon YM, Hwang SG, Kim BS, et al. The efficacy and safety of telbivudine in Korean patients with chronic hepatitis B [in Korean]. Korean J Hepatol 2007 Dec; 13(4): 503–12

    Article  PubMed  Google Scholar 

  62. O’Brien CB, Jia J, Zeldin G. Chronic hepatitis B genotype B or C E antigen positive patients: viral suppression, HBeAg loss and seroconversion rates are improved with telbivudine compared with lamivudine: results from a pooled analysis [abstract no. 255]. Gastroenterology 2008 Apr 1; 134 (4 Supp. 1): 760

    Google Scholar 

  63. Liaw Y-L, Wursthorn K, Thongsawat S, et al. Telbivudine-induced HBeAg seroconversion in chronic hepatitis B (CHB) is durable during 2 years off-treatment follow-up [abstract poster no. 1012]. 45th Annual Meeting of the European Association for the Study of the Liver (EASL); 2010 Apr 14–18; Vienna

  64. Wang Y, Thongsawat S, Gane EJ, et al. Efficacy and safety outcomes after 4 years of telbivudine treatment in patients with chronic hepatitis B (CHB) [abstract no. 482 plus poster]. 60th Annual Meeting of the American Association of the Study of Liver Diseases (AASLD); 2009 Oct 30–Nov 3; Boston (MA)

  65. Safadi R, Xie Q, Chen Y, et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24 [abstract]. J Hepatol 2007; 46 Suppl. 1: 196–7

    Article  Google Scholar 

  66. Dou X, Ding Y, Wang S, et al. Telbivudine suppressed HBV DNA and HBeAg simultaneously in HBeAg-positive chronic hepatitis B (CHB) patients, a two-center clinical study [abstract no. 499]. 60th Annual Meeting of the American Association of the Study of Liver Diseases: 2009 Oct 30–Nov 3; Boston (MA)

  67. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. Epub 2010 Aug 19

  68. Cai W, Xie Q, An B, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48(1): 22–6

    Article  PubMed  CAS  Google Scholar 

  69. Wursthorn K, Wedemeyer H, Manns MP, et al. Quantitation of serum HBeAg levels during prolonged telbivudine treatment and correlation with outcome [abstract plus poster no. 187]. 20th Asian Pacific Association for the Syudy of the Liver (APASL); 2010 Mar 25–28; Beijing

  70. Chen W, Hou JL. Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAgpositive and negative chronic hepatitis B [in Chinese]. Zhonghua Ganzangbing Zazhi 2009 Aug; 17(8): 569–73

    PubMed  Google Scholar 

  71. Hu M, Chen W. Cost effectiveness of telbivudine vs. entecavir and lamivudine among patients with HBeAg-positive chronic hepatitis B in China [abstract no. 1103]. 7th World Congress of the International Health Economics Association; 2009 Jul 12–15, Beijing

  72. Tsoi KKF, Lui YYN, Wong VWS, et al. Cost-effectiveness analysis of antiviral treatment strategies based on the Roadmap Model in chronic hepatitis B virus (HBV) infection [abstract no. PE078]. Hepatol Int 2009; 3: 105

    Google Scholar 

  73. Lui YY, Tsoi KK, Wong VW, et al. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antiviral Ther 2010 Jan; 15(2): 145–55

    Article  CAS  Google Scholar 

  74. Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008; 26(11): 937–49

    Article  PubMed  Google Scholar 

  75. National Institute for Health and Clinical Excellence. Telbivudine for the treatment of chronic hepatitis B [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/TA154Guidance.pdf [Accessed 2010 Mar 12]

  76. Buti M, Brosa M, Casado MA, et al. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009 May 20; 51(4): 640–6

    Article  PubMed  CAS  Google Scholar 

  77. Avila C, Goncalves J. Creatine kinase elevations during 4-years of continuous telbivudine treatment are transient and not predictive of uncommonly observed muscle-related symptoms [abstract no. 472 plus poster]. 60th Annual Meeting of the American Association of the Study of Liver Diseases; 2009 30 Oct–3 Nov; Boston (MA)

  78. Laeufle R, Mayer H, Avila C. Assessment of the risk of peripheral neuropathy with telbivudine: analysis of the telbivudine global clinical safety database [abstract plus poster no. PP010]. 19th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2009 Feb 13–16; Hong Kong

  79. Trylesinski A, O’Connor K, Kraev S, et al. Outcomes for newborns exposed to telbivudine during pregnancy: retrospective analysis of the Novartis safety and clinical databases [poster no. 189]. 20th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2010 Mar 25–28; Beijing

  80. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, et al. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008 Mar; 8(3): 167–78

    Article  PubMed  CAS  Google Scholar 

  81. Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007; 133: 1458–65

    Article  PubMed  CAS  Google Scholar 

  82. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008 Dec; 6(12): 1315–41

    Article  PubMed  CAS  Google Scholar 

  83. Gane EJ. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int 2008 Sep; 2(3): 304–7

    Article  PubMed  Google Scholar 

  84. Ahn S-H, Kweon Y-O, Paik S-W, et al. Telbivudine combination with adefovir versus adefovir monotherapy in HBeAg-positive chronic hepatitis B patients with lamivudine resistance [poster no. PP184]. 20th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2010 Mar 25–28; Beijing

Download references

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Kate McKeage & Susan J. Keam

Authors
  1. Kate McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kate McKeage.

Additional information

Various sections of the manuscript reviewed by: S.H. Ahn, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; G.S. Cooke, Department of Infectious Diseases, Imperial College London, London, UK; J-D. Jia, Beijing Friendship Hospital, Capital Medical University, Beijing, China; D.J. Suh, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; K. Wursthorn, Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Data Selection

Sources: Medical literature published in any language since 1980 on ‘telbivudine’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE, EMBASE and AdisBase search terms were ‘telbivudine’ and ‘hepatitis B’. Searches were last updated 23 August 2010.

Selection: Studies in patients with chronic hepatitis B who received telbivudine. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Telbivudine, hepatitis B, nucleoside analogue, pharmacodynamics, pharmacokinetics, therapeutic use.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McKeage, K., Keam, S.J. Telbivudine. Drugs 70, 1857–1883 (2010). https://doi.org/10.2165/11204330-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11204330-000000000-00000

Keywords

Search

Navigation